Intracranial Aneurysm
Conditions
Keywords
aSAH
Brief summary
The purpose of this research study is to determine if the diameter and flow of the superior mesenteric artery in patients with aneurysmal subarachnoid hemorrhage undergoing hypertensive therapy for cerebral artery vasospasm are effected enough to justify withholding enteral nutrition.
Detailed description
Study measurements of the diameter and Doppler flow velocity of the superior mesenteric artery (SMA) using abdominal ultrasound in order to evaluate the potential additional risk of non-occlusive mesenteric ischemia (NOMI) and non occlusive bowel necrosis (NOBN) in patients undergoing hypertensive therapy for cerebral vasospasm in Aneurysmal Subarachnoid Hemorrhage (aSAH), to justify the withholding of enteral nutrition.
Interventions
DEVICEUltrasound
Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) for a aneurysmal subarachnoid hemorrhage using abdominal ultrasound.
Sponsors
University of Florida
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Patient diagnosed with aSAH
Exclusion criteria
* Hemodynamic instability * Already receiving vasopressor therapy * Non-aneurysmal SAH * Intracranial hemorrhage of other cause * Not anticipated to receive hypertensive therapy with vasoactive medications for cerebral vasospasm from SAH or suspected aSAH * Unable to visualize SMA using ultrasound * Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change between baseline and 21 days of abdominal ultrasound measurement of the diameter in the superior mesenteric artery | Change from baseline up to 21 days |
| Change between baseline and 21 days of abdominal ultrasound measurement of the doppler flow velocity in the superior mesenteric artery | Change from baseline up to 21 days |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with non-occlusive mesenteric ischemia (NOMI) | Change from baseline up to 21 days | Number of participants with non-occlusive mesenteric ischemia (NOMI) undergoing hypertension therapy with vasoactive medications for cerebral arterial vasospasm in aneurysmal subarachnoid hemorrhage (aSAH). |
| Number of participants with non occlusive bowel necrosis (NOBN) | Change from baseline up to 21 days | Number of participants with non occlusive bowel necrosis (NOBN) undergoing hypertension therapy with vasoactive medications for cerebral arterial vasospasm in aneurysmal subarachnoid hemorrhage (aSAH). |
Countries
United States
Outcome results
None listed